

## Formulation of an Extended Release Melatonin Dietary Supplement

### Formulation of Dietary Supplements

Direct compression of dietary supplements may be challenging due to low or high concentration and poor physicochemical properties of active ingredients. Typical challenges include:

- Poor flow and compressibility
- Content uniformity
- Sensitivity to environmental heat, humidity, and light
- Strong odor and/or bitter taste

Therefore, formulators must understand the properties of the active ingredients and choose the right excipients that will provide the formulation properties needed for successful manufacture and stability of the finished dosage form.

### The Challenge

Melatonin acts by inducing sleep and restoring the inherent sleep rhythm that is related to the rise and fall of blood melatonin concentrations. Melatonin treatment helps to restore these human circadian rhythms, resulting in better cognition and less daytime fatigue.<sup>1</sup> As a dietary supplement, synthetic melatonin is available over the counter (OTC) in many forms, including tablets, liquids, patches, gummies, and sprays.<sup>2</sup> As a tablet, melatonin is available in immediate release (IR), extended release (ER), and combination forms. Exogenous administered melatonin has a short half-life (< 1-hour)<sup>3</sup> so ER forms of melatonin are marketed as improving sleep duration and may help patients who awaken intermittently or too early.

This study shows the use of hypromellose (METHOCEL<sup>™</sup> Premium Cellulose Ethers) to formulate a melatonin tablet that provides fast onset of drowsiness and ER to improve sleep duration and avoid morning drowsiness.

### Materials and Methods

Both IR and ER melatonin tablets (5 mg dose) were formulated in this study to assess the impact of hypromellose polymers on dissolution performance. Microcrystalline cellulose (Avicel 102, Dupont) and Starch 1500<sup>®</sup> partially pregelatinized maize starch (Colorcon, Inc.) were used as diluents to help improve blend compressibility and flow (Table 1).

**Table 1. Glucosamine Tablet Formulation**

Core Tablet Ingredient	Category	IR		MR	
		% w/w	mg Tablet <sup>-1</sup>	% w/w	mg Tablet <sup>-1</sup>
Melatonin	Active	1.67	5.00	1.67	5.00
MCC (90-micron)	Diluent	61.50	184.50	56.50	169.50
Starch 1500®	Diluent	35.83	107.49	30.83	92.49
METHOCEL™ K100 LV	ER Polymer	-	-	5.00	15.00
METHOCEL™ E50 LV	ER Polymer	-	-	5.00	15.00
Colloidal Silicon Dioxide	Glidant	0.50	1.50	0.50	1.50
Magnesium Stearate	Lubricant	0.50	1.50	0.50	1.50
	<b>Total</b>	100.00	300.00	100.00	300.00

A part of the Starch 1500 was combined with the colloidal silicon dioxide (10:1) and passed through a 40 US mesh (425 micron) screen to break up agglomerates. A 50 gram batch was prepared by mixing the active and other ingredients for 10 minutes, adding lubricant (pre-screened with a 60-mesh screen) and mixing for a further 3 minutes.

Tablets were compressed using 13/32" (10.3 mm) standard round concave B-tooling using 1500 psi compression force.

Tablet physical testing includes weight, thickness, and breaking force (n=10 tablets). The weight of each tablet was measured to the nearest 0.1 mg using an analytical balance. Thickness of each tablet was measured using a digital caliper and reported to the nearest 0.1 mm. Tablet breaking force (hardness) was measured using a hardness tester. For the friability test 10 tablets were tested for 100 drops. Initial weight of 10 tablets and weight of the 10 tablets after 100 drops were recorded to calculate the friability result. ER dissolution testing (n=3) was performed in 500 mL of water at 37.0°C ±0.5°C using USP Apparatus II (paddles) at 50 rpm for 12 hours, with samples taken at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, and 12.0 hour intervals. Ultraviolet absorbance spectroscopy (UV) at 222 nm wavelength and cell size of 5.0 mm was used for all readings.

Uniformity of dosage testing (n=10) was performed in 50 mL of 25:75; Acetonitrile:Buffer (pH 3.5) diluent at a wavelength of 222 nm and blank correction at 400 nm and cell size of 5.0 mm. One tablet was placed in 50 mL of diluent and homogenize for 5 minutes at 5,000 rpm. The solution was transferred to a 50 mL centrifuge

tube and centrifuge for approximately ten minutes at 3,000 rpm. The supernatant liquid was used for analysis with the diluent as the blank.

Tablets were coated with blue pigmented Nutrafinish® TiO2 Free Film Coating, to 3% weight gain (w/w), in a perforated coating pan (Labcoat™ Benchtop Tablet Coating System, O'Hara Technologies (Table 2).

**Table 2: Film Coating Process Parameters**

Coating System	Nutrafinish® TiO2 Free Coating
Dispersion Solids Content (%)	20
Pan Speed (rpm)	25
Air Volume (cfm)	80
Atomizing Air Pressure (psi)	10
Pattern Air Pressure (psi)	10
Spray Rate (g/min)	6
Inlet Temperature (°C)	60
Exhaust Temperature (°C)	43-44

## Results

Both IR and ER formulations were compressed without any issues and yielded defect-free tablets with good physical properties (Table 3). Content uniformity showed an Acceptance Value of 5.7, demonstrating suitability of the formulation for direct compression. Tablets were successfully coated with the Nutrafinish TiO2 Free coating (Figure 1) providing the added benefit of protection for the light sensitive melatonin active. As expected, the IR formulation released greater than 90% release of the active in less than 30 minutes. The ER formulation, showed greater than 30% active release in the first 30 minutes followed by extended release. This release pattern demonstrates ability of the tablet formulation to provide fast onset and ER to improve sleep duration and avoid morning drowsiness.


**Table 3: Tablet Properties of IR and ER Melatonin Tablets**

Property	IR Tablets	ER Tablets
Weight (mg)	300.1 ±0.00	300.9 ±0.00
Thickness (mm)	4.127 ±0.03	4.222 ±0.03
Hardness (kP)	16.9 ±0.8	16.1 ±0.7
Friability (%)	0.02	0.01
Acceptance Value (CU)	5.7 (PASS)	

**Figure 1: Coated Tablets**



**Figure 2: Dissolution profile for IR and ER Melatonin Tablets**



**Summary**

A low dose extended release melatonin tablet was produced with hypromellose as the rate controlling polymer in combination with Starch 1500 and MCC as diluents. The formulation produced a robust tablet with good content uniformity demonstrating the applicability of direct compression for the formulation. The resulting release pattern of the melatonin active exhibited fast onset and ER to help improve sleep duration and avoid morning drowsiness.

## References

1. Savage RA, Zafar N, Yohannan S, Miller JMM. Melatonin. 2021 Aug 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 30521244.
2. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. *Lancet* 2011; 378: 621–31.
3. Auld F, Maschauer E, Morrison I, Skene D, Riha R, Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders, *Sleep Medicine Reviews* (2016), doi:10.1016/j.smr.2016.06.005.
4. USP Monographs, Dietary Supplement Monographs, Melatonin Tablets. USP-NF. Rockville, MD

*METHOCEL™ is a trademark of International Flavors and Fragrances Inc. or its affiliates.*

© 2021 IFF. All rights reserved.

The information contained herein, to the best of Colorcon, Inc.'s knowledge is true and accurate. Any recommendations or suggestions of Colorcon, Inc. with regard to the products provided by Colorcon, Inc. are made without warranty, either implied or expressed, because of the variations in methods, conditions and equipment which may be used in commercially processing the products, and no such warranties are made for the suitability of the products for any applications that you may have disclosed. Colorcon, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damages.

Colorcon, Inc. makes no warranty, either expressed or implied, that the use of the products provided by Colorcon, Inc., will not infringe any trademark, trade name, copyright, patent or other rights held by any third person or entity when used in the customer's application.

For more information, contact your Colorcon representative or call:

North America <b>+1-215-699-7733</b>	Europe/Middle East/Africa <b>+44 (0)-1322-293000</b>	
Latin America <b>+54-11-5556-7700</b>	India <b>+91-832-6727373</b>	China <b>+86-21-61982300</b>

You can also visit our website at [www.colorcon.com](http://www.colorcon.com)



© BPSI Holdings LLC, 2023.

The information contained in this document is proprietary to Colorcon, Inc. and may not be used or disseminated inappropriately.

All trademarks, except where noted, are property of BPSI Holdings LLC.

*METHOCEL™ is a trademark of International Flavors and Fragrances Inc. or its affiliates.*  
© 2021 IFF. All rights reserved.

Melatonin\_St1500\_V1\_02072023